U.S. Markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.57+1.29 (+6.06%)
At close: 04:00PM EDT
22.20 -0.37 (-1.64%)
After hours: 06:36PM EDT
Sign in to post a message.
  • B
    Have a look at ticker ILUS as well my fellow investors, they are uplisting in 2022. ILUS is a little over a year old and has been profitable every quarter.
    ILUS Q1, 2022 revenue is up 482% over Q1, 2021. This does not even include the revenue from a couple of their most recent acquisitions.
    ILUS just announced a 100-million dollar plus in revenue acquisition.
    This news came out of Yahoo Finance on 5/25/2022.
    In addition to this large acquisition, ILUS has just announced that they have acquired Wikisoft, ticker WSFT. WSFT is now a member of the ILUS family.
    ILUS manufactures EV's, UAV's, and Drones to name a few of their many business endeavors. They are an M & A company and growing fast.
    ILUS is about to begin manufacturing the E-Raptor, the worlds first and only six-wheel electric utility vehicle. This will take place at the new 600,000 square foot facility in Serbia. It is a part of the significant deal that ILUS has recently signed with the European Union.
    Please see the ILUS / Raptor website.
    ILUS holds patented firefighting / safety technology as well.
    ILUS has completed "8" acquisitions in the last 16 months. Vira Drones is one of the more significant. The estimated valuation is over 1 billion dollars.
    ILUS is also reducing their number of outstanding shares by 180 million shares, in addition to all the other excellent news they have recently released. Please see OTC Markets for their most recent share reduction that has been posted. They always do what they say they will do, always.
    ILUS International has also entered into a massive agreement with the European Union and will begin manufacturing a variety of vehicles including those used by the military and defense sectors in Europe, as well as the private sector. Phase one of this contract has just recently been announced. Phase two will follow soon. ILUS is at least worth a look, certainly undervalued.
    (Please see Yahoo Finance for recent news & updates)
  • a
    Agios is the death trap, no pipe line, mitapavit more sales people than patient, removed R &D 50%, useless management, where is buy back
  • H
    Henry D
    How long before the Board steps up and fulfills their fiduciary responsibility?
  • J
    Agio ..continues it’s 12 month decline NEW LOW JUNE 1 ….OLD HIGH $62 JUNE 6 2021 !!!! FOUSE takes AGIO 65% LOWER in 12 months !!!! Hip hip hooray
  • J
    Lol..Pandora ..2nd qtr 2022 is…and your post of triple digits on agio has become a laugh….Xmas and the holidays’s June in two weeks. And Fouse is giving you new lower , never seen before LOWS. !!!! 😂😂😂😂
  • Y
    Yahoo Finance Insights
    Agios Pharmaceuticals reached a 52 Week low at 21.48
  • G
    AGIO market cap is less than cash they have in the bank and they keep buying back share at a huge pace. Way undervalued
  • A
    AGIO has $1.4B in cash on the balance sheet, and an approved product for an initial indication that will generate $500MM in the US and more in Europe. Its being tested in phase 3 for several much larger indications. So the market cap for all of that? $1.6B. I am doubling my position
  • G
    AGIOS has a market cap at about 3.5 billion. Their going to buy back over a billion in share or about 1/3 of outstanding stock. That should take it over 150 per share or much higher on the short squeeze.
    "Agios also announced that its board of directors authorized the repurchase of up to $1.2 billion of its outstanding shares after the close of the transaction. Agios expects to conduct the share repurchases over the next 12-18 months, including executing a meaningful portion of the planned repurchases by year-end through a combination of 10b5-1 plans, open market purchases and potentially privately negotiated block sales."
  • S
    CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the global Phase 3 ACTIVATE trial of mitapivat in adults with pyruvate kinase (PK) deficiency who do not receive regular transfusions met its primary endpoint.
  • K
    $SRPT conversation
    FromSY investing:
    Cantor 2020 #biotech outlook

    Top picks:
    - Large-cap: $VRTX $AMGN
    - Mid-cap: $SRPT $ALNY
    - Small-cap: $TGTX $ICPT $GBT $AGIO
    - Favorite binary: $MYOK
  • P
    Bogus gump from $50.00 to $32.00 was to set up a cheap buy for the onco portfolio. this deal will not happen at the current price.
  • P
    $33.75 bought 10,000 shares. I guess i will find out if the selling is over, but the shorts on this board don't seem to know much about the company.... just complain about the ceo.
  • z
    good entry point.loaded some shares towards closing.
  • O
    – Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency – – Additional ... In case you are interested
    – Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients – – Safety Profile.
    – Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients – – Safety Profile.
  • J
    HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $98
  • P
    Glioblastoma....That Trial can send this stock to $100+ if successful
  • J
    Interesting …nothing important has developed at ALNY, similarly nothing at AGIO….yet, mgmt at ALNY knows how to speak and interest Biotech investors to put their work’s value at a all time high this week. AGIO, has done the opposite in that same week and share price is 1/3 that of an investment in ALNY. So, smart money stills sees a problem with the FOUSE style and mgmt of a Biotech. The facts are in the value of both stocks, evident this week.
  • L
    soooooooooo AGIO releases compelling data on their therapy in trial, with hugely positive affects on subjects tested with almost no side affects 17 hours ago. that was the headline. THEN Yahoo decides to run the "Edited" transcript from the earnings report from over a month ago FOR THE 3RD TIME from Reuters. These shorts are manipulating the stock and the news that affects it.
    SEC should investigate these crooked manipulators.
  • F
    FDA approved IDH1 inhibitor Ivosidenib for treatment of adult acute leukemia. however, no response in stock market